In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma

Canine mammary carcinomas (CMC) are associated with major aggressive clinical behavior and high mortality. The current standard of care is based on surgical resection, without an established effective treatment scheme, highlighting the urgent need to develop novel effective therapies. Vascular endot...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Georgina A. Cardama, Paula L. Bucci, Jesús S. Lemos, Candela Llavona, Micaela A. Benavente, Eva Hellmén, María Laura Fara, Eduardo Medrano, Eduardo Spitzer, Ignacio A. Demarco, Patricia Sabella, Juan Garona, Daniel F. Alonso
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2023-08-01
Serie:	Animals
Ämnen:	canine mammary carcinoma bevacizumab MB02 biosimilar vascular endothelial growth factor
Länkar:	https://www.mdpi.com/2076-2615/13/15/2507
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!